-
Ethics of Sham Surgery Controls to Test Novel Parkinson's Disease Interventions
… trials for PD. We were able to leverage the funding from our Rapid Response Innovation Award to obtain a R01 award from NINDS to continue this line of research. As part of …
-
DPI-289, a Novel Bi-Functional Delta Agonist / Mu Antagonist (DAMA) as a Therapy for Parkinson's Disease
… Pre-clinical models with focal dopamine depletion resulting from 6-OHDA micro-delivery to the midbrain responded with … observed through the full 15 days of dosing. Following on from this crucial demonstration that the DAMA target has the …
-
Search for Specific Retinal Biomarkers of Parkinson’s Disease
… and pathological alpha-synuclein accumulation. The retinas from the eyes of autopsied PD and non-PD subjects will be … the accuracy of the diagnosis of PD during life varies from about 60 percent, within the first few years of …
-
The Role of Phosphorylation and Oligomerixation on Alpha-synuclein-induced Vesicle Rupture
… stress by releasing digestive enzymes (called cathepsins) from these endocytic vesicles. Relevance to … new targets to halt the development of symptoms that arise from neuronal death and dysfunction in Parkinson’s disease …
-
Synthetic Nurr1 Ligands as Novel Neuroprotective Therapeutics to Treat Parkinson’s Disease
… also shows that it protects midbrain dopamine neurons from neuroinflammation-induced death. Therefore, Nurr1 … disease (PD). Based on encouraging preliminary data from our laboratory, we propose to identify and characterize …
-
Efficacy and Safety of APL-130277 in People with Parkinson’s Disease who are Apomorphine Naïve
… and include people who have Parkinson’s disease who suffer from off episodes. These studies are planned to be completed … 15 out of 19 patients dosed with APL-130277 converted from the “off” to the full “on” state. All 15 turned fully …